Merrill maintains Myriad at buy

Myriad Genetics Inc. was kept at its buy rating by Merrill Lynch analyst David Munno after the company presented data demonstrating continued benefits on cognition, behavior and function through 24 months of taking Flurizan for Alzheimers'. Patients who rolled over to Flurizan from the placebo arm also experienced slower decline in cognitive and behavioral function, indicating that Flurizan can change the course of patients' decline with Alzheimers' disease over the long term. Shares of the Salt Lake City-based biopharmaceutical company were up $1.22, or 5.45%, at $23.60 on volume of 393,462 shares versus the three-month running average of 354,489 shares. (Nasdaq: MYGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.